Paraneoplastic syndromes are a group of disorders that are associated with malignant diseases (cancers) but are not directly related to the physical effects of the primary or metastatic tumors ([@A5]). The term \"paraneoplastic\" was coined in the 1940s; however, paraneoplastic conditions have remained poorly understood until recently. Current understanding of paraneoplastic syndromes attributes the disease states either to tumor secretion of functional peptides and hormones, or to immune cross-reactivity between tumor and normal host tissues ([@A6]). The secretion of functional peptides and hormones by tumor tissue is responsible for endocrine paraneoplastic syndromes such as the syndrome of inappropriate antidiuretic hormone secretion, humoral hypercalcemia of malignancy, Cushing syndrome, and carcinoid syndrome.

Paraneoplastic neurologic disorder, in addition to various dermatologic, rheumatologic, and hematologic paraneoplastic syndromes, is caused by immune cross-reactivity between tumor and normal host tissues. The classification of PND is long and includes many rare neurologic conditions. Encephalomyelitis, limbic encephalitis, subacute cerebellar degeneration, opsoclonus-myoclonus syndrome, Lambert-Eaton myasthenic syndrome (LEMS), and acquired neuromyotonia are some of the more common presentations ([@A5]).

Few studies address the incidence and prevalence of PND in the overall population of patients with cancer. One study found that 4% of women with breast cancer, 16% of men with lung cancer, and 6.6% of patients with all cancers had evidence of PND compared with 1% to 2% of age-matched controls ([@A1]). Data described by Rees ([@A7]) suggest that PND usually presents later in life, with a median age of onset of 66 years. Conflicting data exist regarding the sex ratio of patients with PND, demonstrating both female and male predominance ([@A7]). This seems to vary based on geographic location; however, no identifiable pattern has been described.

Although the presentation of PND is possible in the setting of any malignancy, it is most commonly seen in association with cancers that express neuroendocrine proteins, affect organs with immunoregulatory properties, or contain neuronal tissue. Interestingly, cancer is not observed in about 20% of cases of PND, probably reflecting successful control of tumor growth and metastasis by the host immune system ([@A7]). One of the most common and notorious PND-associated malignancies is lung cancer ([@A2]). The frequency of PND in lung cancer patients may reach 30%, and the presence of well-defined onconeural antibodies has been observed in 20% of these patients ([@A11]; [Table 1](#T1){ref-type="fig"}).
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PATHOGENESIS
============

The clinical features of PND can be attributed to the presence of autoantibodies that are produced in response to a primary malignancy. These antibodies are termed \"onconeural antibodies.\" Onconeural antibodies and associated onconeural T lymphocytes inadvertently attack both tumor cells and components of the nervous system ([@A5]). These antibodies react with both intracellular and extracellular antigens, including nuclear proteins and membrane channels. They are thought to arise as a result of the aberrant expression of antigens common to tumors and neurons ([@A7]).

Known onconeural antibodies have been reported in fewer than 50% of patients with PND; therefore, the absence of known antibodies does not rule out the presence of PND. Standard investigations such as blood tests, CT and MRI scanning, and CSF analysis are rarely useful in confirming a diagnosis of PND ([@A7]). The diagnosis often rests either on the demonstration of an underlying malignancy (if not already known) or on the presence of circulating onconeural antibodies, often demonstrated using a battery of serum tests commonly known as a paraneoplastic panel.

**Antivoltage-Gated PotassiumChannel Antibodies**

Many autoantibodies have been identified in patients with paraneoplastic syndromes. The paraneoplastic panel performed on the serum of our patient, RS, was positive for anti-VGKC antibodies. Voltage-gated potassium channels are highly relevant to neuronal and muscular physiology given their vital contribution to the cellular action potential. They are specifically implicated in initiating paraneoplastic autoimmunity. Serum antibodies reactive with VGKC were initially reported as markers of acquired neuromyotonia and are also found in Morvan syndrome, a rare autoimmune condition consisting of irregular contractions of the long muscles, cramping, weakness, pruritus, hyperhidrosis, severe insomnia, and delirium ([@A8]). While RS's signs and symptoms do not meet all criteria for Morvan syndrome, it is reasonable to suspect that the presence of anti-VGKC autoantibodies is implicated in her clinical presentation.

DIAGNOSIS AND MANAGEMENT
========================

Unfortunately, patients with PND are often severely disabled at the time of diagnosis, and no attempt at treatment is effective. Immunomodulatory therapies such as corticosteroids, azathioprine, cyclophosphamide, and plasma exchange are often tried but, with the exception of the treatment of LEMS, have generally been unsuccessful ([@A7]). Rituximab and intravenous immunoglobulins have also been used; however, the impact of these therapies remains unclear because the number of patients treated is low, patients also receive antineoplastic therapy, and randomized prospective studies are lacking ([@A4]). Diagnosis and treatment of the underlying malignancy remains the mainstay of treatment for PND ([Table 2](#T2){ref-type="fig"}).
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CONCLUSION
==========

In the case of RS, a diagnosis of paraneoplastic encephalopathy was made based on her clinical presentation and the presence of anti-VGKC antibodies on her paraneoplastic panel. The medical oncology team consulted the neurology and neuro-oncology services who first recommended 5 days of high-dose IV methylprednisolone sodium succinate. When this failed to elicit a significant response, plasma exchange was pursued. Five total treatments were planned. RS received 3 treatments with no improvement. A percutaneous endoscopic gastrostomy tube was placed for the purposes of providing nutrition in the hopes of sustaining the patient to undergo further testing, and possibly cancer treatment if her neurologic status improved with plasma exchange. RS developed health-care--associated pneumonia as a result of her debility and extended hospital stay and was eventually transferred to a medical intensive care unit. At this point, according to her wishes, her husband requested that no further aggressive treatment be pursued. She was discharged home with hospice and expired approximately 1 week after discharge.

IMPLICATIONS FOR THE ONCOLOGY ADVANCED PRACTITIONER
===================================================

Paraneoplastic encephalopathy is a rare condition seen in patients with underlying cancer. Although immunomodulatory therapy such as corticosteroid administration and plasma exchange is sometimes helpful in reducing morbidity and mortality, most patients diagnosed with PND are unlikely to improve significantly due to deconditioning and debility at the time of diagnosis. The purpose of this case study is to raise awareness and understanding of this disease state. It is hoped that a broader understanding of paraneoplastic neurologic disorders will assist oncology APs in researching, educating our peers, and counseling our patients about signs and symptoms to monitor, so that we may promote earlier diagnosis and treatment of this devastating syndrome.
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